Connecting you to content on EBSCOhost

Works matching AU Bi, Yanyu

Results: 4

1

Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/β-catenin signaling and autophagy.

Published in:

Journal of Cancer Research & Clinical Oncology, 2021, v. 147, n. 2, p. 499, doi. 10.1007/s00432-020-03422-4

By:

Bi, Yanyu;
Jiang, Yiming;
Li, Xia;
Hou, Guoxin;
Li, Kesang

Publication type:

Article

2

Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2017, v. 66, n. 4, p. 475, doi. 10.1007/s00262-016-1949-8

By:

Chen, Cheng;
Li, Kesang;
Jiang, Hua;
Song, Fei;
Gao, Huiping;
Pan, Xiaorong;
Shi, Bizhi;
Bi, Yanyu;
Wang, Huamao;
Wang, Hongyang;
Li, Zonghai

Publication type:

Article

3

A novel approach for the analysis of single-cell RNA sequencing identifies TMEM14B as a novel poor prognostic marker in hepatocellular carcinoma.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-36650-y

By:

Ma, Ding;
Liu, Shuwen;
He, Qinyu;
Kong, Lingkai;
Liu, Kua;
Xiao, Lingjun;
Xin, Qilei;
Bi, Yanyu;
Wu, Junhua;
Jiang, Chunping

Publication type:

Article

4

ERCC6L is a biomarker and therapeutic target for non–small cell lung adenocarcinoma.

Published in:

Medical Oncology, 2022, v. 39, n. 5, p. 1, doi. 10.1007/s12032-022-01654-7

By:

Hou, Guoxin;
Lu, Zhimin;
Bi, Yanyu;
Deng, Jingjing;
Yang, Xinmei

Publication type:

Article